194 related articles for article (PubMed ID: 19517457)
1. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
[TBL] [Abstract][Full Text] [Related]
2. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
[TBL] [Abstract][Full Text] [Related]
4. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
5. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
6. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
7. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
[TBL] [Abstract][Full Text] [Related]
8. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
[TBL] [Abstract][Full Text] [Related]
9. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
Sato J; Yanagawa T; Dobashi Y; Yamaji T; Takagishi K; Watanabe H
Clin Exp Metastasis; 2008; 25(4):427-35. PubMed ID: 18301993
[TBL] [Abstract][Full Text] [Related]
12. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience.
Kim DH; Kim SY; Lee HJ; Song BS; Kim DH; Cho JB; Lim JS; Lee JA
Cancer Res Treat; 2011 Sep; 43(3):170-5. PubMed ID: 22022294
[TBL] [Abstract][Full Text] [Related]
14. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.
Chang KJ; Kong CB; Cho WH; Jeon DG; Lee SY; Lim I; Lim SM
Skeletal Radiol; 2015 Apr; 44(4):529-37. PubMed ID: 25431093
[TBL] [Abstract][Full Text] [Related]
18. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
19. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
20. Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography.
Casey DL; Wexler LH; Fox JJ; Dharmarajan KV; Schoder H; Price AN; Wolden SL
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1136-42. PubMed ID: 25539372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
